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Abstract
Background: The use of genomic sequencing techniques is increasingly being
incorporated into mainstream health care. However, there is a lack of agreement
on how “incidental findings” (IFs) should be managed and a dearth of research
on patient perspectives.
Methods: In‐depth qualitative interviews were carried out with 31 patients under-
going genomic sequencing at a regional genetics service in England. Interviews
explored decisions around IFs and were comparatively analyzed with published
recommendations from the literature.
Results: Thirteen participants opted to receive all IFs from their sequence, 12
accepted some and rejected others, while six participants refused all IFs. The key
areas from the literature, (a) genotype/phenotype correlation, (b) seriousness of
the condition, and (c) implications for biological relatives, were all significant;
however, patients drew on a broader range of social and cultural information to
make their decisions.
Conclusion: This study highlights the range of costs and benefits for patients of
receiving IFs from a genomic sequence. While largely positive views toward the
dissemination of genomic data were reported, ambivalence surrounding genetic
responsibility and its associated behaviors (e.g., duty to inform relatives) was
reported by both IF decliners and accepters, suggesting a need to further explore
patient perspectives on this highly complex topic area.
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1 | INTRODUCTION
The appropriate handling of “incidental findings” (IFs) is an
issue that has long concerned medical practitioners (Ofri,
2013). IFs have been defined as findings that have “health or
reproductive importance for an individual, discovered in the
course of conducting a particular study (screening or clinical
practice) but beyond the scope of that study” (Christenhusz,
Devriendt, & Dierickx, 2013). From the identification of an
enlarged gallbladder, to a benign brain tumor during routine
investigations for other conditions, healthcare professionals
in various fields of medicine frequently have to make judg-
ments in the course of their clinical practice about whether
patients should be informed of these findings given that they
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are unsolicited medical information, often of unclear signifi-
cance, and for which prior consent to obtain them has not
typically been secured.
While genetic medicine is already an area where the
discovery of IFs is particularly common (Christenhusz
et al., 2013), the increasing application of genomic
sequencing and exploratory (as opposed to targeted) analy-
sis techniques within mainstream NHS Healthcare has fur-
ther compounded this issue. Indeed, the sheer volume of
data that can be generated and analyzed through the use of
genomic sequencing has been revolutionized by the emer-
gence and increasing cost‐effectiveness of new technolo-
gies. Due to this exponential rise in available data, the
potential for IFs to emerge in the context of genomic
research and clinical practice has correspondingly soared,
raising important ethical and social issues around the
acceptability of their identification and, more pertinently,
their (non)disclosure to genomic medicine patients.
While it has been widely acknowledged that the bound-
aries between “clinically significant” and “clinically action-
able” findings within a genomic sequence are often highly
uncertain or even malleable (when interpreted in the con-
text of other relevant health data; Knoppers, Joly, Simard,
& Durocher, 2006), their very generation raises significant
questions around whether or not patients have the right to
access them. Studies that have explored the attitudes of
researchers, healthcare professionals, patients, and the gen-
eral public have consistently demonstrated enthusiasm for,
and interest in, receiving IFs on the parts of both the gen-
eral public and genomic medicine patients, highlighting
that the latter two groups harbor the most permissive views
around the return of unsolicited genomic findings than any
other stakeholder group (Bollinger, Scott, Dvoskin, &
Kaufman, 2012; Driessnack et al., 2013; Fernandez et al.,
2014; Haga, O’Daniel, Tindall, Lipkus, & Agans, 2011;
Middleton et al., 2016; Ploug & Holm, 2017; Townsend
et al., 2012; Yushak et al., 2016).
In the context of public and patient demand to receive
them, therefore, ethical arguments both for and against the
return of IFs have been extensively rehearsed in the litera-
ture in recent years (Berkman & Hull, 2014; Christenhusz
et al., 2013; Gilwa & Berkman, 2013; Hens, Nys, Cassi-
man, & Dierickx, 2011; Hofmann, 2016; Shkedi‐Rafid,
Dheensa, Crawford, Fenwick, & Lucassen, 2014). Within
this literature, it has been suggested that both extreme posi-
tions in this debate (i.e., the case for full disclosure of IFs
and the case for their complete nondisclosure) are ethically
unacceptable (Christenhusz et al., 2013). In other words,
both withholding potentially relevant health information
from patients, but also indiscriminately disclosing all unso-
licited findings are both viewed as both morally deplorable
strategies. Indeed, the latter requires substantial (and often
nonexistent) resources to be successfully implemented,
whereas the former has been critiqued for its inherent
paternalism and neglect of duty of care (Ravitsky & Wil-
fond, 2006; Townsend et al., 2013).
In order to reach an ethically sound solution to the
problem of genomic IFs both in clinical practice and in
sequencing research, various taxonomic systems have been
developed to guide decisions around which IFs should be
returned to patients and which should not (see Table 1).
These taxonomies use categories or “bins” (Berg, Khoury,
& Evans, 2011) to group similar IFs together in order to
determine whether they should be returned to patients.
While the categories used vary between studies and
authors, the taxonomies generally coalesce around the fol-
lowing three distinct constituent components:
1. The strength of the genotype/phenotype correlation. This
area of categorization addresses the diversity of gene pen-
etrance and expressivity and includes IFs that relate to
predispositions rather than certain genetic disease (e.g.,
Berg et al., 2011; Boycott et al., 2015; Klitzman et al.,
2013; Leitsalu et al., 2016; Wolf et al., 2008)
2. The impact, severity, and treatability of the associated
genetic disease(s). This dimension of IFs appears most
commonly across the taxonomies and determines the
management of the IF based on the likelihood of symp-
toms, the age at which they will occur, their severity, as
well as the degree to which the condition can be pre-
vented or ameliorated through an intervention such as
treatment or surveillance (e.g., Bennette, Gallego,
Burke, Jarvik, & Veenstra, 2015; Hens et al., 2011;
Himes et al., 2017; Knoppers, Deschênes, Zawati, &
Tassé, 2013; Korngiebel et al., 2015; Mayer et al.,
2011; Netzer, Klein, Kohlhase, & Kubisch, 2009; Séné-
cal et al., 2015; Van El et al., 2013).
3. The relevance of the IF beyond the index case. This
area of categorization incorporates the rights and inter-
ests of biologically related kin to the patient, including
IFs that may impact the health of existing relatives, or
decisions around childbearing, for example, carrier sta-
tus (e.g., Klitzman et al., 2013; Netzer et al., 2009).
The evidence used to support these taxonomies
(Table 1), however, has largely been developed by clini-
cians and professional bodies, with far less data available
on the way in which sequencing patients and the general
public make decisions. Where the views and decisions of
genomic sequencing patients and their families have been
included, studies have mostly emphasized their liberal atti-
tudes toward the dissemination of IFs, both inside and out-
side the clinic (Clift et al., 2015; Kaphingst et al., 2016).
While there is evidence that greater ambivalence exists
around IFs that relate to children (especially when the IF is
not clinically actionable and/or relates to a late‐onset
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condition; Kleiderman et al., 2014; Sapp et al., 2014; Ziniel
et al., 2014), the literature nevertheless suggests that the
majority of sequencing patients overwhelmingly support
the sharing of all IF information that is available to the
clinician, so long as the patient requests it.
As most NHS genomic sequencing is undertaken to
facilitate a diagnosis, and, as such, on people already living
with unspecified long‐term health conditions, it has been
argued that these groups of patients are better equipped
(than members of the general public) to cope with
TABLE 1 Taxonomies used to classify types of incidental findings to aid decision‐making about their return
Authors
Empirical or
Literature‐based Study Taxonomy
American College of
Medical Genetics and
Genomics (2013),
American College of
Medical Genetics and
Genomics (2014),
Green et al., (2013)
Literature A list of 56 genes for 24 inherited disorders that should always be returned if found as
an IF, regardless of the patient’s age or reasons for undergoing genomic sequencing.
Amended in 2014 to allow opt‐out.
Bennette et al. (2015) Empirical
(patients’ views)
The following attributes should be evaluated in relation to any IF in order to determine
whether or not it should be returned:
Lifetime risk of disease
Disease treatability
Disease severity
Whether it has reproductive implications (carrier status)
Berg et al. (2011) Literature IFs should be classified as follows:
Bin 1: clearly deleterious variants with immediate clinical utility. These should be
returned.
Bin 2: variants with a known or presumed association with a disease/trait but not
medically actionable. Their possible return should be discussed with the patient at the
point that consent is taken.
Bin 3: variants of unknown or no clinical significance. These should not be returned.
Boycott et al. (2015) Literature Adults
Captious adults should be given the option to receive IFs (excluding those of uncertain
significance or low‐penetrance dispositions).
For adults lacking capacity, highly penetrant medically actionable conditions should be
reported to their representative.
Children
In children, only highly penetrant actionable (during childhood) conditions should be
reported to parents.
Adult‐onset disorders in children should only be reported if the parents request it, or
disclosure could prevent serious harm to the parent or another family member.
European Society of
Human Genetics
(2013), Hens et al.
(2013)
Literature Unsolicited genetic variants should only be returned if it is indicative of a serious health
problem, either in the person tested or in their close relative(s).
Hens et al. (2011) Literature The following should always be returned in adults and children:
Treatable/preventable disease
All other IFs that do not fit into the above category should only be returned if requested
by adult, and only once a child reaches 18 and consent renegotiated.
Himes et al. (2017) Empirical Carrier status IFs should only be returned if the condition to which the carrier status
relates the following:
Limits the lifespan
Requires significant medical involvement
Causes significant physical, cognitive, or sensory impairment
Demands significant daily care and/or care cost to the family
Is risky for the mother during pregnancy
Can be treated to significantly mitigate or reverse symptoms
(Continues)
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uncertain or “bad news” results (Hitch et al., 2014), fea-
tures that may characterize an IF. However, as genomic
sequencing frequently relies on sequencing, not only the
index case, but also other members of their (extended) fam-
ily—those with less experience and knowledge of genetic
disease—are also being called upon to make decisions
TABLE 1 (Continued)
Authors
Empirical or
Literature‐based Study Taxonomy
Klitzman et al. (2013) Empirical: surveys
and interviews
IFs that fall into the following eight categories should be returned:
Category 1: high penetrance with the possibility of clinical intervention (treatment/
surveillance)
Category 2: high penetrance without the possibility of clinical intervention
Category 3: modest penetrance with an associated clinical intervention
Category 4: modest penetrance without an available clinical intervention
Category 5: IFs with reproductive implications for the proband
Category 6: IFs with reproductive implications for the children of the proband
Category 7: pharmacogenetic variants that influence response to drugs
Category 8: IFs that have the potential to be relevant and of interest to the proband, but
have no clinical implications (e.g., paternity)
Knoppers et al. (2013) Empirical IFs should always be returned if the following criteria are met:
Consent: Consent has been given by the patient
Validity: The IF has been confirmed independently
Seriousness: The IF poses a serious risk of a serious condition and is actionable.
IFs may be considered for return if the following criteria are met:
Consent: The patient has given consent
Validity: The IF has been confirmed independently
Risk: It poses an established risk to the health of the patient
Treatment: There is therapeutic benefit to disclosure.
Korngiebel, West,
and Burke (2018)
Empirical: focus
groups and surveys
The following categories of IF should be returned:
Lifespan limiting (childhood): IFs that lead to conditions where 50% of affected children
die before age 10.
Serious: default category. If the phenotype is variable, this category is used only if
>50% of affected people have the most severe form.
Moderate/mild: symptoms not life‐threatening with only mild/moderate disruption to
normal activities. Treatment, if available, is not burdensome.
Unpredictable: wide range of severity in phenotype. Factors such as age of onset and
severity vary widely.
Late onset: conditions for which symptoms do not appear until after 20.
Leitsalu (2016;
Adapted from
Berg et al., 2011)
Literature and surveys Bin 1: medically actionable.
Bin 2a: low risk
Bin 2b: medium risk
Bin 2c: high risk
For Bin 1, IFs should be returned for all known/presumed deleterious gene variants. For
Bins 2a, 2b, and 2c, reporting of all known/presumed deleterious gene variants should
be done only if elected by the patient, through shared decision‐making with an
appropriate healthcare specialist.
Mayer et al. (2011) Empirical: case study Treatable diseases in children: information that will directly impact the care of the child.
Adult‐onset treatable diseases: information on adult‐onset disease that could be treated
in adulthood.
Adult‐onset nontreatable diseases: returned on a case‐by‐case basis.
Netzer et al. (2009) Literature and
clinical observations
The following IFs should be returned:
Predictive value: findings that have future implications not only for the health of the
proband, but also their family.
Availability of treatment: IFs for which effective treatment options (including
surveillance programs) exist.
Carrier status: IFs that reveal carrier status for autosomal recessive disorders that may
have reproductive implications for their proband and/or their family.
(Continues)
1082 | BOARDMAN AND HALE
around the return of IFs. However, the effect such contex-
tual factors (such as prior experience with genetic disease)
have on patients’ decision‐making and the reasons patients
refuse receipt of genomic information have generally been
under‐researched.
This paper explores this identified gap in the literature
through a qualitative study of the views of people undergo-
ing genomic sequencing as part of Genomic England’s
100,000 Genomes Project. Taking as its analytic framework
the taxonomies developed by clinicians and researchers to
classify and define various different types of IF (Table 1),
this paper offers an in‐depth comparison of the views of 31
genomic sequencing patients (13 of whom accepted IFs
and 18 of whom refused some or all IFs offered to them)
with those of genetics professionals (as expressed in the lit-
erature) in order to identify areas of concordance and dis-
cordance between the perspectives and priorities of these
two important stakeholder groups. By taking the patient’s
perspective as a point of departure, this paper contributes
to a small but emerging body of the literature designed to
better understand the processes through which patients
come to accept or decline IFs and, consequently, how they
can be supported through this.
1.1 | 100,000 Genomes Project
The 100,000 Genomes Project is a Genomics England ini-
tiative that aims to sequence 100,000 genomes from
approximately 70,000 people who are either NHS patients
with a rare disease or cancer or their unaffected family
members, in order to assist with obtaining a diagnosis and/
or to facilitate research for their condition.
Participants in the 100,000 Genomes Project receive
the results of their genomic sequence as two components:
(a) the “main finding” from their genomic sequence,
which concerns the health issue they came to the project
with; and (b) additional findings (referred to throughout
this paper as IFs) that were discovered surreptitiously
during the sequence. Only variants deemed clearly patho-
genic (or with a high likelihood of becoming pathogenic)
and where an early intervention is both available, and
deemed beneficial, are authorized for return within the
project (see Table 2). These IFs are then subcategorized
into two types: health‐related IFs (i.e., findings that relate
to health conditions that could affect the participant and/
or their biologically related kin) and reproductive IFs
(findings that relate to conditions that will likely not
affect the participant, but could be passed on to off-
spring). Participants in the 100,000 Genomes Project can
choose to accept either, both, or neither of the types of
IFs. They may also accept or decline individual findings
within each of these two broad categories. As the list of
authorized IFs is likely to expand over time, either
because new genes are identified, the variant is recatego-
rized (e.g., if a treatment becomes available), or a new
category of IFs is added to the list, participants are made
aware at the start of the project that they could poten-
tially be contacted in years to come with an IF result. As
such, informed consent in this context is an ongoing
rather than one‐off event.
TABLE 1 (Continued)
Authors
Empirical or
Literature‐based Study Taxonomy
Sénécal et al. (2015) Literature and
consultation process
IFs concerning a child must be returned when:
They meet criteria of scientific and clinical validity
have significant health implications
effective treatment or prevention is available and can begin during childhood/
adolescence;
has approval from parents
has been confirmed by an accredited clinical diagnostic laboratory.
IFs concerning a child should not be returned when:
They concern future health or predisposition to late‐onset disorders
or when consent has not been received from a parent
Wolf et al. (2008) Literature The following categories of IF should be returned:
Findings that offer strong net benefit: These findings reveal conditions that are
potentially grave or life‐threatening and can be treated.
Findings that offer possible net benefit: findings that a research participant/patient may
deem important, even if the condition cannot be avoided (e.g., findings related to
susceptibility)
The following IFs should not be returned:
Findings that have unlikely net benefit: conditions of no clinical significance that are not
life‐threatening and have no reproductive significance. This includes findings with
undetermined clinical significance. These findings should not be returned.
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There are currently six health‐related IFs on the list of
approved IFs (five relating for cancer predispositions and
one for familial hypercholesterolemia) with children dis-
qualified from receiving any IF that relates to an adult‐on-
set condition (see Table 2). Currently, cystic fibrosis is the
only reproductive IF that is being returned. Furthermore, as
cystic fibrosis is inherited recessively, this finding is only
returned if both members of a couple participate in the pro-
ject and both agree to receive it.
2 | METHODS
The data presented within this paper are derived from inter-
views with 31 patients who underwent genomic sequencing
as part of the 100,000 Genomes Project at a large regional
Genomic Medicine Centre in England. The data were col-
lected between October 2017 and March 2018. These inter-
views were part of a larger study that compares the views
of the general population taking part in genomic sequenc-
ing research with the views of individuals and families liv-
ing with genetic conditions (Boardman & Hale, 2018).
Interview participants were identified through 100,000
Genomes Project clinic lists held by the regional genetics
service. Participants were considered eligible if they were (a)
volunteering for genomic sequencing as part of the 100 K
Genomes Project, (b) over the age of 18, (c) had either
accepted or declined Ifs, and (d) were able to communicate
fluently in English without the need for an interpreter. Ini-
tially, genomic medicine clinic staff conducted the identifica-
tion of potential participants through clinic lists and mailed
out participant information sheets to 100 eligible genomic
sequencing patients with a covering letter. This initial strat-
egy of recruitment led to the successful recruitment of 22
participants, although all those who responded were IF
accepters. Given that the overwhelming majority of genomic
sequencing volunteers accept all IFs associated with their
sequence, purposive sampling was employed to selectively
target IF decliners. A second round of 40 letters were sent
out, exclusively to IF decliners (including those who had
declined some, but accepted other IFs), which yielded only
two responses. In a final attempt to increase the number of
IF decliners, follow‐up phone calls were made to each of the
participants who had not responded to the letter as well as to
the six decliners who had received a letter in the first round.
This strategy of undertaking a follow‐up phone calls led to
the successful recruitment of a further 16 IF declining partic-
ipants (see Table 3).
The interview schedule was developed by reference to
the literature surrounding genomic sequencing, the 100,000
Genomes Project’s policy on IFs and from interviews con-
ducted, as part of the same study, with families living with
genetic diseases (Boardman & Hale, 2018). The interview
schedule for this study covered participants’ experiences
of, and views toward, both genomic sequencing and
genetic screening, their perceptions of genomic information
vis‐à‐vis other forms of health data, as well as their prior
knowledge of genetic conditions, particularly cystic fibro-
sis, a condition for which an IF could feasibly be returned.
Finally, participants were asked to recount their decision‐
making around accepting or declining IFs and their antici-
pated uses of this information should an IF be returned to
them.
Interviews were conducted via three methods, face‐to‐
face interviews (n = 8), telephone interviews (n = 22), and
email interviews (n = 1). The choice of interview method
was determined primarily by the participant’s preference,
ability, and health status. Face‐to‐face interviews were car-
ried out either at the participant’s home or at the university.
All interviews were transcribed verbatim (or responses col-
lated within one document for the email interview) with
names, place names, and any other identifiers removed. As
such, all names reported in this paper are pseudonyms.
The data were analyzed with the help of NVivo 11
qualitative data analysis software. Open coding was con-
ducted first to identify core themes (e.g., “stories of geno-
mic sequencing involvement” and “meanings of genetic
data”), before more specific subthemes were developed
(e.g., “meaning and value of the return of carrier status as
an additional finding”). A modified grounded theory
approach to the analysis was used to generate new themes
from the data, but also to cross‐reference the themes with
the three key areas of classification that emerged from the
IF taxonomies in the literature (Table 1) in order to com-
pare professional and lay classifications of IFs. This paper
presents the three core overarching themes, but also the
subthemes that emerged from this analysis.
TABLE 2 Incidental Findings currently being returned by
100,000 Genomes Project
Health‐related incidental findings
and variants looked for
Reproduction‐related
incidental findings and
variants looked for
Bowel cancer predisposition: MLH1
(adult only), MSH2 (adult
only), MSH6 (adult only), MUTYH
(adult only), APC (adult and child)
Cystic fibrosis (CFTR)
Breast and ovarian cancer
predisposition: BRCA1 (adult only),
BRCA2 (adult only)
Other cancer predisposition: VHL
(adult and child), MEN1 (adult and
child), RET (adult and child)
Familial hypercholesterolemia: LDLR
(adult and child), APOB (adult and
child), PCSK9 (adult and child)
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2.1 | Editorial policies and ethical
considerations
Ethical approval for the study was granted through the
Health Research Authority in September 2017 (17/WM/
0240 01/08/2017).
All participants in this study signed a consent form (or
gave permission by email—where the participant was phys-
ically unable to write) indicating that they had been fully
informed about the nature of the interview, as well as the
likely uses of their data. All names and identifiers were
removed during transcription of the interviews.
TABLE 3 Participant characteristics and IF decisions
Participant
Accepted
reproductive
incidental
findings?
Accepted
health‐related
incidental
findings? Gender Age Status Condition in family
Peter YES YES Male 80 Proband Ataxia
Malcolm YES YES Male 38 Proband Cancer
Ivan YES YES Male 78 Proband Heart condition
Harvinder YES YES Female 65 Proband Heart condition
Jennifer YES YES Female 31 Sister Leopard syndrome
Roger YES YES Male 59 Proband Hereditary spastic paraparesis
Niall YES YES Male 26 Proband Friedreich’s ataxia
Emma YES YES Female 40 Mother Limb deformities
Lola YES YES Female 21 Mother Congenital ichthyosis
Jane YES YES Female 51 Proband Ataxia
Joanna YES YES Female 38 Mother Ataxia, hydratonia, hypermobility, and global
developmental delay.
Ian YES YES Male 38 Father Dyspraxia and global development delay.
Abi YES YES Female 44 Mother Retinitis pigmentosa.
Heather NO YES Female 65 Aunt Aortic aneurism
Mary NO YES Female 60 Proband Heart condition
Frank NO YES Male 71 Brother Ataxia
Natalie NO YES Female 41 Brother Hereditary spastic paraparesis and multiple sclerosis
Helen NO YES Female 36 Proband Desmoid tumor and bowel cancer
Hallie NO YES Female 48 Mother Hearing loss
Nicola NO YES Female 57 Mother Cancer
Sarah NO YES Female 25 Proband Retinitis pigmentosa
Louisa NO YES Female 44 Mother Retinitis pigmentosa
Karen NO YES Female 40 Mother Mayer–Rokitansky–Küster–Hauser (MRKH)
syndrome
Laura NO YES Female 35 Proband Hypermobility Ehlers Danlos syndrome
Lee NO YES Male 43 Father Retinitis pigmentosa.
Rhona NO NO Female 42 Proband Burst heart murmur, only one kidney, absent uterus,
and bone structure issues
Simon NO NO Male 42 Father Ataxia, hydratonia, hypermobility, and global
developmental delay.
Samantha NO NO Female 42 Mother Dyspraxia and developmental delay
Bethany NO NO Female 42 Mother Unknown degenerative disorder
Toby NO NO Male 34 Proband Muscular dystrophy
Jane NO NO Female 41 Mother Cognitive impairment
Note. Blue: accepted all incidental findings; Green: accepted some incidental findings, Orange: refused all incidental findings.
BOARDMAN AND HALE | 1085
3 | RESULTS
In total, 31 genomic sequencing volunteers took part in an
interview, of which, 13 (42%) participants accepted both
health and reproductive IFs, 12 (39%) accepted health‐re-
lated IFs but not reproductive Ifs, and six (19%) partici-
pants refused all IFs (Table 3). IF decliners are over‐
represented in our sample as their perspectives are both
poorly understood and under‐represented in the literature.
Participants ranged in age from 21 to 80, with an average
age of 46. The vast majority of the sample, 21 (68%), were
women. Twenty‐eight (90%) participants were undergoing
genomic sequencing due to an undiagnosed rare disease in
their family, with three (10%) coming from a family
affected by cancer. Thirteen participants (42%) were the
“index case” in the family, that is, the person with the rare
disease or cancer, meaning that the majority, 18 (58%),
were unaffected family members. These family members
included 11 mothers, three fathers, two brothers, one sister,
and one aunt (see Table 3).
The results of the analysis are presented according to
the three major themes used to classify IFs identified from
the literature (Table 1).
3.1 | The geno/phenotype correlation
The core theme of geno/phenotype correlation was a recur-
rent theme across the literature on the return of IFs in clini-
cal practice and research (Table 1). While for professionals,
this theme appraises IFs where the penetrance or expressiv-
ity of a genetic mutation is not clear (Klitzman et al.,
2013), for sequencing volunteers, this theme emerged
through their understandings and visualizations of the com-
plex process by which a genomic finding comes to be man-
ifested physically as a genetic disease.
In order to explore the views of sequencing volunteers
on this correlation, as well as the way(s) in which it influ-
enced decisions around accepting or refusing the return of
IFs, participants were encouraged to discuss their motiva-
tions for getting involved with the 100,000 Genomes Pro-
ject, their perceptions of genomic data (and the way(s) it
might differ from other forms of health data), and its rela-
tionship to genetic diseases.
It was clear that from the outset that genomic data held
a very particular status for participants in the project,
although many found it difficult to pinpoint in exactly what
ways. For some, the very difficulties associated with
accessing the data and the need for specialist interpretation
were part of what made the information precious and valu-
able, highlighting its complexity but also its invulnerability
to manipulation, as Malcolm, a 38‐year‐old man and father
of a young son who had joined the 100,000 Genomes Pro-
ject due to cancer in his family commented:
[Genomic data]…. It’s not something you can
hide from, it’s not something you can make
up, it’s not something you can manipulate.
Your DNA is your DNA, simple as that. So
you can’t manipulate that. So to me that’s
more of a pure, data more pure science than
numbers that are taken from averages from
surveys. This is, it’s deeper than that. It’s real,
honest data. …the holy grail if you will.
Unlike other health data—such as weight and height,
which fluctuate over the life course and are not unique to
an individual—a person’s genome was viewed, by many
participants, as an inimitable and static entity. For Mal-
colm, a person’s genome was the formula underpinning
their human existence, the source from which all other
physical and mental characteristics as well as health experi-
ences emerged. Unlike health data, it also had social signif-
icance, forming the biological link connecting family
members past, present, and future. It was this perception of
his genomic data as an integral part of his personal, famil-
ial, and social identity, with the various responsibilities that
be perceived as accompanying these identities that were
key to Malcom’s ultimate decision to receive all IFs gener-
ated from his sequence, even those that were uncertain:
Well I think [incidental findings], I think it’s
all very important. Because it gives you
insight into yourself‐ what could come and
bite you… it just, it gives you… it takes away
some of the guess work because it gives you
an educated guess to go actually this could,
this follows a trend it’s being passed on…[…]
… You know…. And I want to see my son
grow up, I want to see him have his own fam-
ily. So if it helps…. not my generation but
their generation, then I’ll be happy with that,
you know.……But it’s also, unless people are
willing to participate fully in things like this
[100,000 Genomes Project], then you’re never
going to get that information…it would need
to be everyone being screened…for it to then
really progress. But people then would then
say that’s the government wanting all your
details, and all your DNA. But… idiots really.
Actually, you know, it’s bigger than you.
They just feel like it’s an invasion of privacy,
but it’s not.
For Malcolm, his perceived responsibilities to maintain
his own health, protect that of his son, but also to con-
tribute to a wider project of genomic data accumulation
that could be used to address major health problems such
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as cancer were all important in his decision to become fully
involved with the research and to receive as much informa-
tion from his genome as possible.
The intertwining of genomic data, personal identity,
responsibility, and altruism was frequently mentioned dri-
vers behind participants’ decisions to opt to receive all IFs
they could, even those with reduced expressivity, with par-
ticipants citing reasons such as “wishing to understand
themselves,” “curiosity about who I am,” or “wanting to
help others” to justify their decision to receive findings
where their clinical implications were not clear‐cut. Partici-
pants also cited the possibilities of preventative treatments/
lifestyle changes, screening (either self‐screening or as part
of a formalized screening program), and reduced time to
diagnosis as possible advantages of knowing about propen-
sities in their genetic makeup.
For other participants, however, the uncertainty associ-
ated with IFs of variable expressivity rendered the results
less meaningful and led to different understandings of
responsibility. Simon was 42 years old at the time of
interview and described joining the 100,000 Genomes
Project because of his young daughter, Dasiy, who has
ataxia, hydratonia, hypermobility, and global developmen-
tal delay of unknown origin. For Simon, his interest in
the project was very specific—gaining a diagnosis for
Daisy, with the associated hope of improving the man-
agement of her condition. He declined both reproductive
IFs (saying that he and his wife, Jo—who was also vol-
unteering for the project—would not have another biolog-
ical child, but would instead choose to adopt) as well as
health‐related IFs, which he viewed as being of limited
value to his life. Simon described his decision in the fol-
lowing way:
So from my point of view I’m… I’ve isolated
anything that can help and is to do with Daisy
and that’s fine. Conditions that I may have
that may come up in the future, I don’t really
want to know about to be honest. It is what it
is. I wouldn’t have known [if hadn’t partici-
pated in 100,000 Genomes Project], and if
something came up and they went “oh, by the
way, you’ve got an 80% chance‐ or whatever‐
of having cancer”, or having this, or having
whatever else, will that change the way I live
my life? Probably. Would it have a massive
effect on my family and me? Yes. Do I want
that? No. If something comes up in the future,
it comes up in the future. I’d be no different
as I was before it came. So yeah, no, I think, I
don’t know, I think in some instances know-
ing something, especially when it’s not even
definite…you’ve got an 80% chance of having
something at some point in the future can
define how you live your life and could actu-
ally destroy your life…[…]…and I have a
good life….So I don’t really, I wouldn’t really
want to upset it for any reason, for something
may or may not happen. I don’t kind of, I
don’t think like that.
Simon viewed propensities to genetic disease, rather
than being part of his personal identity and sense of self as
Malcolm had, as instead belonging to a particular mindset,
or approach to life, which had been developed through his
experiences of living with, and caring for, Daisy:
That’s the thing, you know, Daisy, you know,
she’s got a condition, and it’s step‐by‐step,
you deal with what comes up, and the more
information that comes up, you find something
else to help it, you know, and you try and pro-
gress through it. You don’t… it’s no good…
it doesn’t benefit me or Daisy or Jo if we’re
worrying about what’s going to happen in ten
years’ time. I can’t…. I can’t enjoy what I’m
doing now, but I also can’t, function and do,
you know…. how are you going to deal with
your day‐to‐day knowing what might happen?
So yeah, not me. I wasn’t really interested in
anything other than that.
While it has been suggested that people with experience
of chronic health conditions are better able than those with-
out to process and respond to uncertain and complex health
information such as genetic propensities (Hitch et al., 2014;
Sapp et al., 2014), like many parents of disabled children
with high support needs and uncertain or life‐limiting prog-
noses, Simon described an approach to managing his day‐
to‐day life that focused on immediate need (Heiman,
2002). Unlike Malcolm, who viewed the retrieval of as
much information as possible from his sequence as an
enactment of his “genetic responsibility” (Kenen, ) toward
his son, for Simon, acting responsibly instead meant
eschewing this information to retain a clear focus on the
present. By so doing, Simon was better able to cope with,
and enjoy, his current reality with Daisy, undisturbed by
the potential pain of future‐orientated and uncertain health
information.
3.2 | Genetic disease severity and the return
of IFs
For many participants, the acceptability of uncertain health
information (such as a genetic finding of reduced pene-
trance) rested, at last in part, on the severity, impact, and
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availability of treatments for the implicated condition. This
concern applied to both types of IF available through the
100,000 Genomes Project, influencing perceptions of the
utility of health‐related and reproductive (carrier status)
findings.
While the list of conditions for which participants could
be identified as having a predisposition to, or being a car-
rier of, through IFs were limited to seven in the 100,000
Genomes Project (see Table 2), in describing examples of
what they considered to be “serious,” participants sponta-
neously mentioned a range of diseases. The most com-
monly mentioned were cancers and heart conditions (both
n = 6); followed by motor neuron disease (n = 3), cystic
fibrosis, multiple sclerosis, diabetes, and blood disorders
(all n = 2). The following conditions were also sponta-
neously mentioned by one participant each as an example
of conditions that can be serious in their presentation:
arthritis, Down’s syndrome, dyspraxia, dyslexia, asthma,
cerebral palsy, dementia, lung conditions, kidney condi-
tions, and sexual diseases. While specific conditions were
listed as examples by many participants, there was a wide
variety of interpretations as to what “serious” meant, and
an acknowledgment that it encompassed a range of social,
environmental, psychological, as well as biological factors.
Due to this broad understanding of the impact of a genetic
disease, participants frequently referred to different types of
experience with a condition (such as “pain” or “restricted
mobility”) without these necessarily being ascribed to a
single diagnosis. Jennifer, for example, a 31‐year‐old
woman who accepted all IFs and was participating in the
project due to an undiagnosed condition in her sister
described a serious condition in terms of the degree to
which it affected life opportunities and independence:
Anything that would impede like a normal life
physically or mentally where they couldn’t
grow to be an adult and they were dependent
for their whole life. I’d consider that serious if
they couldn’t go to a normal school and have a
normal education and be independent. So that
probably covers a lot of things [diagnoses].
However, for other participants, unpicking the severity
of a condition from other factors, such as the likelihood of
it ever developing and the social and environmental context
in which the condition is experienced, was near‐impossible.
While components of this information (e.g., geno/pheno-
type correlation) were viewed as largely objective informa-
tion, however, judgments on disease severity were
considered to be far more nuanced, idiosyncratic, and sub-
jective, causing some participants to question whose role it
was to make the judgment on where the boundaries around
it should be drawn. Karen was 40 years old at the time of
her interview, had refused reproductive IFs, and was the
mother to a young daughter, Molly, who was suspected to
have Mayer–Rokitansky–Küster–Hauser (MRKH) syn-
drome (a condition characterized by the absence of sex
organs). While Karen acknowledged that disease severity
was an important consideration in determining whether
people should receive IFs, she called into question the
authority of the medical profession to decide how severity
should be defined, and therefore which results she would
have the option of receiving;
…..More severe, you know, more severe kind
of conditions are the ones that are going to
affect… I suppose if they’re, you know, if a
condition affects your life, your quality of
life…[…]… although that’s different for each
person……And I think, I think that’s the,
there’s a line somewhere‐ so this is the thresh-
old of things we give the information or not,
but anything above this line we don’t give the
information…..But I would hope not, I would
definitely not agree with that. I don’t think
you can ever hold back someone’s information
after you’ve got that information, but I think
you have to say everything above this line we
need to consider that all the facts and where
the benefits and detrimental effects could be
for this person, before giving that information.
But then who is making that decision? What
right have they got to make a decision? So
there needs to be a, you know, I presume a
very, very strict protocol you would need to
go through to make a decision on who knows
what, but I wouldn’t want to be the one mak-
ing those kinds of decisions!
Like Karen, many other participants also thought that
the medical profession should take into account the per-
son’s character (including their tendency toward anxiety
and depression) when considering whether or not to return
IFs, leading some to argue that findings related to mild
conditions should not be returned at all. Natalie was 41 at
the time of her interview and was participating in the
100,000 Genomes Project on account of her brother’s diag-
nosis with spastic paraparesis and her daughter’s diagnosis
of multiple sclerosis. While Natalie opted to receive health‐
related AFs from her sequence, she situated her ideas about
the return of “mild” IFs and predispositions within a con-
sumerist and commercially driven cultural milieu which
she perceived as bringing with it a particularly low toler-
ance of risk:
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I don’t know, I think you’ve got to work with
the individual, you know? I think there’s prob-
ably lots of push out there for people to want
to know if there’s something the matter with
them, we want to control everything. And
everything is serious now, no one ever says
they have a headache, it’s always a migraine.
And I’ve been… a lot of it is to do with
finances as well, whether or not you can find
these things out….whether you can get a
house and get insurance, if you are right for
this job, that sort of thing. And sometimes I
think you can just frighten people without
good cause really. So if it’s mild I really don’t
think you need to know. I mean, we’ve done
ok without knowing about them so far.
For participants such as Natalie, living in a risk‐adverse
society which emphasizes personal responsibility for health
was critical to the push toward an expanding definition of
what “serious” conditions are. Indeed, while accepting
health‐related IFs herself, Natalie simultaneously critiqued
the rationale for providing this form of information in the
first place, reflecting an ambivalence toward genomic med-
icine that was widespread among both IF accepters and
decliners. The co‐existence of seemingly contradictory
views highlights not only the complexity of responses to
IFs (and their situation within broader social and cultural
ideas about health and health behaviors), but also the limi-
tations of understanding patient perspectives on genomic
medicine by recourse to test acceptance or decline alone.
While the majority of participants in this study pre-
sented far more nuanced understandings of what “mild”
and “serious” conditions were that incorporated broader
ranges of modifying factors than those offered within the
professional taxonomies, for other participants, the very
concept of disease severity in relation to IF return was an
entirely moot point. For these participants, using notions of
seriousness or gene expressivity as a filter to determine
which IFs should be returned was unacceptable, primarily
because they viewed their genomic sequence as their own
data, to which they should have full rights of access, irre-
spective of what the data meant.
Mary had just turned 60 and was being treated for a
heart condition at the time of her participation in the
100,000 Genomes Project. While Mary had declined repro-
ductive IFs (which she described as being on account of
her lack of children), she described her views on IFs and
her decision to receive all health‐related ones in the follow-
ing way:
….you know, I think even if it’s a mild condi-
tion….it’s by the by. If somebody else knows
it, then I should know it. I guess the medical
profession are the people that would hold that
information…But I do think that, yes, it’s an
entitlement, I wouldn’t like to think somebody
was keeping it from me. Or at the very least
ask me if I want to know, which is what, you
know, I signed the form to say, yes I would
like to know please, because I don’t think they
have a right to withhold my information.
For participants such as Mary, any harms of not receiv-
ing the information that had been generated from her
sequence were perceived to outweigh the harms of know-
ing, even if they related to conditions that might be consid-
ered mild or unlikely to present. For Mary, ownership of
the data was presented within a discourse of rights and
entitlement and expressed as a desire to make autonomous
decisions over how the data were used. For her, there was
something inherently wrong with another person knowing
more about her health status than she did herself, and
addressing what she perceived as imbalanced access to her
information overrode any of the difficulties associated with
incomplete or flawed information that were raised by other
participants.
The question of who owns genomic information arose
in participants’ accounts not only in relation to disease
severity, however, but also in discussions of participants’
rights and responsibilities to their biologically related kin,
to which we now turn.
3.3 | Incidental findings and biologically
related kin
While participants described accepting health‐related and
reproductive incidental findings for a host of different rea-
sons, both future‐orientated (to assist the development of
cures and treatments; to help plan their lives) and
anchored in the present (enabling them to access tailored
treatments and to better understand themselves), one of
the most commonly mentioned reasons for accepting both
health‐related and reproductive IFs concerned relationships
with biologically related others. Indeed, while not specifi-
cally asked about within the interview schedule, seven
participants spontaneously mentioned that they felt they
had an obligation to ensure that genetic diseases did not
get passed on through their family, and there was evi-
dence of participants experiencing both shame and guilt
when this had occurred. Niall, who opted to receive all
IFs available, was 26 years old at the time he participated
in the 100,000 Genomes Project, with a suspected diagno-
sis of an X‐linked (i.e., expressed in males and transmit-
ted by females) neuromuscular condition. Niall described
the impact his taking part in the project had had, both on
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his relationship with his mother, but also his daughter,
who is likely a carrier:
….I remember phoning my mum and going,
“I’ve been told about this [100,000 Genomes
Project]. And she said “oh”, and one of the
first things she said was “I’m sorry, I didn’t
know”. And I guess she felt bad that she’d
passed [undiagnosed condition] on to me,
because she didn’t know. So yeah, I think
people need to know what’s in their genes so
they won’t have to have that conversation that
me and mum had. And I said “it’s not your
fault mum, I’m sorry”, and then she cried.
And then I felt bad, and I felt bad that I’d
passed that same burden on to my daughter.
So yeah, maybe it would spare people the
future pain or future problems, if they’re just
open and honest, and say “look, this is what
you’ve got, or you could have”, you know,
people should know. Yeah, it was a tough
phone call to have, and then telling my wife
about it, she got really upset. And she said
“well, what if we want more children?” And I
remember just being positive and saying “well,
it might be recessive, and we can have more
children”. But if it’s something that I’m going
to pass on, I’ll be honest, I don’t want them to
have to go through what I go through on a
daily basis. Some days are better than others
and I’m perfectly fine. Other days, I don’t get
out of bed because it’s just too much. Yeah.
So the more people that know the better, it’s
only fair.
Niall's sense of genetic responsibility, not only to his
daughter, but also to his future and as yet hypothetical chil-
dren, had entirely shifting since his participation in the
100,000 Genomes Project. Up until this point, Niall had not
considered the potential genetic origins of his condition, nor
what this information might mean for daughter, wife, and
mother, as well as himself, as they considered both their
future, present, and past reproductive responsibilities.
Indeed, for some participants, the perceived need to
obtain, distribute, and act on genetic information within
families was so powerful that those who did not co‐opt into
such practices were labeled “irresponsible” or even “self-
ish,” as Frank, a 71‐year‐old participant commented:
….Well I think people have to think long and
hard about whether they want to pass some-
thing on, and then take advice. I think it’s
their job really to make sure they tell everyone
who could be affected because basically you
are… maybe bringing somebody into this
world with a problem that you’ve got yourself,
and it may even be worse, and making your
life bad and their life hell…and some people
are just selfish aren’t they? They don’t care if
they, you know if they… if it’s going to affect
somebody else. But I would say it’s your duty
as a human being to look after other human
beings, and certainly those within your own
family, otherwise, where are we going?
While participants most frequently spoke of the need
to disseminate genetic information to biologically related
kin, to inform them both of their chances of developing
the condition, but also their chances of passing it on, for
some participants, this sense of genetic responsibility
was, paradoxically, also the reason they opted to decline
IFs.
Bethany was 42 at the time of her interview and had
joined the project due to an undiagnosed degenerative dis-
order in her teenage daughter. For Bethany, it was not an
absence of a sense of genetic responsibility that influenced
her decision to decline all IFs, but rather her acute aware-
ness of that accountability, and the concomitant possibility
that she might be held responsible and blamed for any
decisions taken if they were made in the context of geno-
mic information:
I think that I just decided that, I thought why
would you really want to know about the car-
rier testing? Because we just were happy to
sort of get on with our life. We didn’t want to
find out something that maybe there was noth-
ing we could do about it, and then have that
hanging over us for the rest of our lives, and
also if you don’t know about something you
can’t get blamed for it either, can you?
Like Niall and Frank, Bethany’s perception of the
strong association between genetic responsibility and “ge-
netic blame” was reflected in her views on IF decision‐
making, even as these participants eventually arrived at
entirely polarized decisions.
In addition to Bethany, other participants who declined
IFs did not necessarily do so as a rejection of their respon-
sibilities to biological kin, but rather because they had a
broader view of those responsibilities, incorporating
responsibilities to promote social justice, acceptance, and
diversity in a society that views genetic impairment in typi-
cally negative ways. Toby, for example, was 34 at the time
of his interview and had been diagnosed with a form of
muscular dystrophy. For Toby, participation in the 100,000
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Genomes Project was about gaining a definitive diagnosis
and access to potentially more suitable treatments. How-
ever, he had concerns about accessing and disseminating
his genomic data beyond the boundaries of this goal.
Indeed, for him, declining all IFs was an active decision to
demonstrate his affirmation of life with genetic impairment:
I suppose I always wonder with that [disclosure
to biologically related kin] how far down the
road are you going to get with that until you’re
starting to verge on eugenics? Well maybe not
that as such but, you know, those kind of
areas….. So, you know, it’s not just affecting
the person who is making the decision [about
IFs], but how do you, how is that decision
going to have an effect on somebody else who
has got that condition, and what are you saying
to them? What you’re saying to them is that,
you know, you shouldn’t have been born, we
want to stop you happening again so we better
make sure everyone knows and does the right
thing. I’m sorry, no. So yeah, that’s my, you
know, I don’t like that, that idea. So, you know,
people say that if the information’s available,
everyone should have it, but should you be get-
ting that information in the first place? I don’t
know, but I think probably not.
Unlike Niall and Frank, Toby’s interpretation of his
genetic responsibility extended beyond his biological fam-
ily to other people with the same condition as him. For
him, reproductive responsibility lays primarily in his rein-
forcement of the intrinsic value of life with a genetic disor-
der, rather than in the prevention of lives affected by them.
Through a dislocation of his genomic data from the dis-
course of rights and entitlement which often surround it,
Toby situated the return of IFs within a sociopolitical con-
text in which the lives of disabled people are valued in
very particular ways.
4 | DISCUSSION
As genomic medicine continues to expand, there are
mounting concerns about how the swathes of data that can
be generated from its usage are accessed, stored, inter-
preted, and communicated to patients (Christenhusz et al.,
2013; Clift et al., 2015; Himes et al., 2017; Klitzman et al.,
2013). Indeed, these concerns are only set to increase as
techniques such as whole genome sequencing enter main-
stream health care, particularly in the fields of diagnostics
and reproduction. While it is hoped that genomic sequenc-
ing will facilitate more accurate diagnoses, tailored treat-
ments, and better information about one’s genomic health,
IFs nevertheless remain a persistently controversial area,
with different views in the published literature on how they
should be managed (Ewuoso, 2016). In spite of this bur-
geoning professional literature, comparatively little is
known about the views of people undergoing genomic
sequencing toward the return of IFs. To the best of our
knowledge, this qualitative study is the first to offer a com-
parative analysis between the decision‐making of geneti-
cists, clinicians, and researchers, with the views,
experiences, and decisions of 31 whole genome sequencing
volunteers who had all recently made decisions about
whether or not to receive them. This study is also one of
the first to include the underexplored perspectives of partic-
ipants who declined Ifs, a minority group within genomic
sequencing patients overall, and a challenging population
to recruit. However, by purposefully oversampling this
group and employing more intensive recruitment strategies
to do so, we were able to conduct a more in‐depth and
substantial analysis of their views.
There was evidence from across the sample that geno-
mic data were held in particularly high regard by those par-
ticipating in the project and considered vastly different to
other forms of health data. The need for specialist techno-
logical input to both access and interpret it, its relevance to
all systems and organs within the body, but, critically, also
its permanency and uniqueness, were are pivotal to the
demarcation of genomic data as the “holy grail” (Malcolm)
of health information. Indeed, for many participants, geno-
mic data were regarded as “trumping” all other forms of
health data—forming the very blueprint for an individual’s
existence.
It was this high status assigned to genomic information
by participants in the study that made the potential of an
imperfect correlation between genomic findings and pheno-
typic expression particularly hard to reconcile. As many par-
ticipants had joined the 100,000 Genomes Project with
expectations of finding a “solid answer” (Hallie) to the health
difficulties affecting their family, IFs that related to predispo-
sitions or that had reduced expressivity posed particular chal-
lenges to deeply entrenched beliefs about the power of
genomic data. Participants typically responded to these
uncertainties by drawing on fatalistic ideas about genomics
in order to minimize its intrinsic uncertainties (e.g., Mal-
colm). While for others—particularly those who rejected IFs
—probabilistic information was likened to a “sword of
Damocles” hanging over them, which, if related to a condi-
tion that could not be prevented, treated, or cured, was con-
sidered to only cause anxiety and reduce enjoyment of life.
This view is also reflected in the professional literature that
argues for restrictions on the return of IFs (Berkman & Hull,
2014) as well as being echoed in the debates that surround
the possible expansion of the newborn bloodspot screening
(Taylor‐Phillips et al., 2014). Indeed, as the “therapeutic
BOARDMAN AND HALE | 1091
gap” (Botkin, 2016; i.e., the chasm that exists between the
capacity to identity genetic diseases and the ability to treat
them) appears to be widening alongside improvements in
detection technologies (of which genomic sequencing is
one), increasing numbers of IFs with highly uncertain
impacts and few available therapeutic options are likely to
continue to appear in the future, suggesting a need for ongo-
ing regular revisions of the criteria used to determine which
IFs should be returned to patients.
However, the likelihood of the genetic disease actually
occurring was not the only factor that participants consid-
ered important when deciding whether or not to receive its
associated IF. The severity of the condition and its antici-
pated trajectory were also considered to be of paramount
importance, both for interview participants, as well as
within published recommendations in the literature (e.g.,
Bennette et al., 2015; Knoppers et al., 2013; Korngiebel
et al., 2015; Sénécal et al., 2015; Wolf et al., 2008; Van El
et al., 2013).
Despite its significance, however, the notion of “seri-
ousness” remains a nebulous and poorly defined concept,
in relation to both whole genome and exome sequencing
(Korngiebel et al., 2015; Nuffield Council on Bioethics
2018; Sapp et al., 2014), but also genomic screening
(Lazarin et al., 2014; Leo et al., 2016; Molster et al.,
2017), with calls for more systematic guidelines on the
classification of different genetic disorders along this
dimension (Ceyhan‐Bisroy et al., 2017; Crouch, 2018).
To navigate this uncertainty, participants in this study
drew on a broad spectrum of lived experience with health,
disease, and disability to make sense of both the IF and
their decision to receive it or not (Etchegary et al., 2008).
Rather than focusing on individual conditions, however,
“experiential categories” were frequently used by partici-
pants as a means by which to decipher severity. Partici-
pants drew boundaries around different types of disease
experience, such as “life‐limiting,” “painful,” and “treat-
able” to cluster groups of conditions together and define
them as either serious or mild. Unlike the classifications
used within the literature that have typically only examined
the medical implications of a disorder (e.g., Korngiebel
et al., 2015; Lazarin et al., 2014), participants’ understand-
ings were both nuanced and broadly contextualized, incor-
porating social, economic, environmental, and
psychological aspects of living with genetic disease.
Indeed, participants not only considered the condition itself,
but were also able to personalize that genetic risk, tailoring
their appraisal of it to their unique set of circumstances and
values (e.g., Simon and Daisy) and using it as a tool with
which to make decisions around the return of IFs.
As well as IF accepters, IF decliners (e.g., Karen) also
considered the severity of the condition associated with an
IF as an important part of their decision‐making. However,
this group expressed far more reticence than IF accepters
about the possibility of being able to appraise the condi-
tion’s severity in advance of it occurring. As has been
highlighted in critiques of IF return from the published lit-
erature (Berkman & Hull, 2014), these participants were
more likely to express concerns over who has the authority
to deem a condition severe (e.g., Karen), as well as to
highlight the fact that definitions of seriousness are likely
to alter over time, reducing the utility of an IF in predicting
severe genetic disease.
A final key feature of the way in which participants
described and understood their genomic information that
cut across all of the three key domains explored was its
tangible relationship to identity—not just personal identity
and sense of self—but also to familial identity. For partici-
pants, it was the identity‐constituting nature of genomic
data that led them to challenge the authority of clinicians
to withhold any IFs that were generated from their
sequence. By understanding IFs through a discourse of
rights and entitlement, these participants discounted the rel-
evance of professional judgments on phenotype expression
and disease severity in determining access to their IFs and
instead regarded their genomic data as belonging a priori to
themselves. While Birch, Townsend, and Rousseau (2012)
have argued that members of the public perceive geneticists
as opening the lid of “Pandora's box” through genomic
sequencing, the findings of this study suggest that many
participants regarded geneticists as having a much less
active and creative role in the generation of IFs, acting
instead as the interpreter through which pre‐existing geno-
mic variants could be accessed and appraised, rather than
contributing to the generation or “release” of new ones.
Prior claims on the ownership of genomic data, how-
ever, not only created tensions in the relationships between
patients and healthcare professionals, but was also played
out in the negotiation of rights and responsibilities within
families. The notion of “genetic responsibility” has been
widely used within the literature to describe the range of
obligations and activities undertaken by those at genetic
risk (D'Agincourt‐Canning, 2001; Hallowell, 1999; Hallow-
ell et al., 2006; Kenen, ). However, the findings of this
study highlight that a broad move away from targeted
genetic testing to an age‐expansive genomic sequencing
brings with it new forms of “genomic responsibility” that
goes beyond previously understood responsibilities. The
most common ways that this genomic responsibility was
referred to within this dataset were in relation to the per-
ceived duty to disclose genetic information to related fam-
ily members whose health could be implicated and/or to
act on future‐orientated genetic risk information that could
minimize the risk of disease in either their future selves or
offspring. However, as this study has highlighted, partici-
pants’ sense of genomic responsibility frequently extended
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beyond the boundaries of their biologically related kin,
reflecting an interest in the emerging project of “social
genomics.” Participants such as Toby, for example, raised
concerns about the directions this project may take in the
future, including its impacts on the lives of disabled peo-
ple. Indeed, this notion of collective responsibility for the
future directions of genomics was significant even for those
participants who declined IFs. For these participants, inter-
preting their rejection of IFs as an expression of apathy
would be to underestimate the powerful discourse of geno-
mic responsibility that they were reacting to. Indeed, the
avoidance of IFs for these participants was not a rejection
or disvalue of genomic information per se, but instead was
a rejection of the perceived responsibilities associated with
that information, for which they did not want to be
“blamed” (Bethany). As such, while advances in genomic
medicine are frequently justified on the basis of their exten-
sion of patient autonomy and choice, this study highlights
the way that accountability to notions of genomic responsi-
bility (personal, familial, and social) can paradoxically
undermine and displace participants’ autonomy—by reduc-
ing the means available to justify and present their deci-
sion, including their right “not to know” (Berkman & Hull,
2014; Hallowell, 1999).
Overall, therefore, this study brings into critical relief
the simultaneously telescopic and expansive effects that the
use of genomic sequencing can have on understandings of
personal and familial health, identities, and roles. By focus-
ing on decisions around the return of IFs, this study high-
lights that participants’ responses to IFs were at once
tightly focused (on one particular variant) but also macro-
scopic, taking into account their personal biographies,
social and biological relationships with known and
unknown others, as well as the broader sociopolitical con-
text in which they lived. Their accounts underscore the
value placed on personal choice and autonomy (and a
rejection of clinical paternalism) in determining which IFs
they should have access to, but simultaneously demonstrate
how broad notions of genomic responsibility can have a
similarly restrictive effect on IF decision‐making as those
imposed by clinicians. By closing down particular ways of
justifying, and accounting for decisions—particularly IF
refusal—participants found themselves navigating difficult
(and not previously well‐trodden) pathways, balancing the
various (and sometimes competing) interests, harms, bene-
fits, and responsibilities associated with IF return, even
when this was at the expense of their own autonomy and
free choice.
5 | FURTHER RESEARCH
Further research may usefully focus on the ways in which
concepts such as reproductive citizenship, genomic
responsibility, and risk may be deployed to better under-
stand the full range of responsibilities and burdens associ-
ated with participation in genomic sequencing research and
clinical practice. As the capacities of genomic medicine
continue to expand and consequently also the list of poten-
tial IFs that could be returned, the involvement of patient
and public groups in decisions surrounding returnable vari-
ants is now of paramount importance.
The expansion of genomic medicine also challenges tra-
ditional methods of gathering informed consent from genet-
ics patients (Lucassen, Montgomery, & Parker, 2016).
Further research that explores patients’ prior experiences
with health and disease, and how these relate to their per-
ceptions of disease severity, may be particularly useful in
assisting the development of patient‐orientated taxonomies
of IF return that could be used to supplement existing clini-
cal taxonomies. Such patient‐orientated taxonomies would
likely include a broader range of social, cultural, and envi-
ronmental factors that are currently not acknowledged in
clinical taxonomies (Table 1), but which are nevertheless
aspects of disease experience that can render it “severe” in
the eyes of patients (e.g., the experience of social stigma
and inaccessible environments). Through the generation of
patient‐centered taxonomies to assist decision‐making, the
process of IF return can be rendered more meaningful, par-
ticularly in contexts where participants are likely to lack
any prior experience and knowledge of the condition in
question.
6 | STRENGTHS AND WEAKNESSES
This study, while representing a wide range of views and
decisions, may nevertheless be biased by its reliance on
100,000 Genomes Project volunteers. As the majority of
the participants in this project were having their genomes
sequenced to assist, primarily, in the diagnosis of a family
member (rather than for their own direct benefit), this may
have contributed to accounts whereby notions of genetic
responsibility were particularly emphasized. In spite of this
limitation, however, the final sample demonstrated an
acceptable level of diversity, with participants having a
wide range of prior experiences with rare disease and can-
cer (see Table 3). IF decliners were also over‐represented
in this study; however, the lack of prior research on their
perspectives counterbalances this sampling bias as it
allowed for a detailed analysis of their (difficult to access)
perspectives, which is ultimately a key strength of this
paper.
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